Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.82 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CA4 | P22748 | 3/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.36 |
| ▸ | TYMS | P04818 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA5A | P35218 | 2/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.35 |
| ▸ | FDPS | P14324 | 2/20 | 0.33 |
| ▸ | MMP2 | P08253 | 2/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL6310117 | 1.00 | SLC34A1 (0.82) | SLC34A1KDM4ECYP2C19KMT2ALMNA | |
| Phosphoric Acid SCHEMBL5745536 | 1.00 | SLC34A1 (0.82) | SLC34A1KDM4ECYP2C19KMT2ALMNA | |
| Phosphoric Acid SCHEMBL27544253 | 1.00 | SLC34A1 (0.82) | SLC34A1KDM4ECYP2C19KMT2ALMNA | |
| Phosphoric Acid SCHEMBL2128094 | 1.00 | SLC34A1 (0.82) | SLC34A1KDM4ECYP2C19KMT2ALMNA | |
| Phosphoric Acid SCHEMBL7623899 | 0.96 | SLC34A1 (0.75) | SLC34A1KDM4ECYP2C19KMT2ALMNA | |
| Phosphoric Acid SCHEMBL2954685 | 0.95 | SLC34A1 (0.90) | SLC34A1KDM4ECYP2C19KMT2ALMNA | |
| Phosphoric Acid SCHEMBL7530569 | 0.95 | SLC34A1 (0.90) | SLC34A1KDM4ECYP2C19KMT2ALMNA | |
| Phosphoric Acid SCHEMBL10787868 | 0.95 | SLC34A1 (0.90) | SLC34A1KDM4ECYP2C19KMT2ALMNA | |
| Phosphoric Acid SCHEMBL5293558 | 0.95 | SLC34A1 (0.90) | SLC34A1KDM4ECYP2C19KMT2ALMNA | |
| Phosphoric Acid SCHEMBL5907878 | 0.95 | SLC34A1 (0.90) | SLC34A1KDM4ECYP2C19KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3472137-A1 | PROCESS FOR PREPARING ATALUREN AND ITS INTERMEDIATES | ScinoPharm Taiwan, Ltd. (TW) | 2019-04-24 | — | — | EP | claimed |
| US-10138215-B2 | Process for preparing ataluren and its intermediates | SCINOPHARM TAIWAN, LTD. (TW) | 2018-11-27 | — | — | US | claimed |
| WO-2017222474-A1 | PROCESS FOR PREPARING ATALUREN AND ITS INTERMEDIATES | SCINOPHARM TAIWAN, LTD. (TW) | 2017-12-28 | — | — | WO | claimed |
| US-20170362192-A1 | PROCESS FOR PREPARING ATALUREN AND ITS INTERMEDIATES | SCINOPHARM TAIWAN, LTD. (TW) | 2017-12-21 | — | — | US | claimed |
| EP-2822929-B1 | PROCESS FOR PREPARATION OF ROFLUMILAST | SCINOPHARM (CHANGSHU) PHARMACEUTICALS LTD (CN) | 2017-06-14 | — | — | EP | claimed |
| US-9085533-B2 | Process for preparation of roflumilast | SCINOPHARM (CHANGSHU) PHARMACEUTICALS, LTD. (CN) | 2015-07-21 | — | — | US | claimed |
| US-20150025246-A1 | PROCESS FOR PREPARATION OF ROFLUMILAST | SCINOPHARM (CHANGSHU) PHARMACEUTICALS, LTD. (CN) | 2015-01-22 | — | — | US | claimed |
| EP-2822929-A1 | PROCESS FOR PREPARATION OF ROFLUMILAST | Scinopharm (Changshu) Pharmaceuticals Ltd. (CN) | 2015-01-14 | — | — | EP | claimed |
| WO-2013131484-A1 | PROCESS FOR PREPARATION OF ROFLUMILAST | SCINOPHARM (CHANGSHU) PHARMACEUTICAL, LTD. (CN) | 2013-09-12 | — | — | WO | claimed |
| CN-117642428-A | Antibodies to | UCB生物制药有限责任公司 | 2024-03-01 | — | — | CN | disclosed |
| EP-3472137-A1 | PROCESS FOR PREPARING ATALUREN AND ITS INTERMEDIATES | ScinoPharm Taiwan, Ltd. (TW) | 2019-04-24 | — | — | EP | disclosed |
| US-10138215-B2 | Process for preparing ataluren and its intermediates | SCINOPHARM TAIWAN, LTD. (TW) | 2018-11-27 | — | — | US | disclosed |
| WO-2017222474-A1 | PROCESS FOR PREPARING ATALUREN AND ITS INTERMEDIATES | SCINOPHARM TAIWAN, LTD. (TW) | 2017-12-28 | — | — | WO | disclosed |
| US-20170362192-A1 | PROCESS FOR PREPARING ATALUREN AND ITS INTERMEDIATES | SCINOPHARM TAIWAN, LTD. (TW) | 2017-12-21 | — | — | US | disclosed |
| US-20150025246-A1 | PROCESS FOR PREPARATION OF ROFLUMILAST | SCINOPHARM (CHANGSHU) PHARMACEUTICALS, LTD. (CN) | 2015-01-22 | — | — | US | disclosed |
| EP-2822929-A1 | PROCESS FOR PREPARATION OF ROFLUMILAST | Scinopharm (Changshu) Pharmaceuticals Ltd. (CN) | 2015-01-14 | — | — | EP | disclosed |
| WO-2013131484-A1 | PROCESS FOR PREPARATION OF ROFLUMILAST | SCINOPHARM (CHANGSHU) PHARMACEUTICAL, LTD. (CN) | 2013-09-12 | — | — | WO | disclosed |
| EP-0851224-B1 | Biosensor with C-shaped counter electrode | MATSUSHITA ELECTRIC INDUSTRIAL CO LTD (JP) | 2002-03-27 | — | — | EP | disclosed |
| US-5985116-A | Biosensor | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 1999-11-16 | — | — | US | disclosed |
| EP-0851224-A1 | Biosensor with C-shaped counter electrode | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 1998-07-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025246-A1 | PROCESS FOR PREPARATION OF ROFLUMILAST | REN, CYP3A5, CYP2C19 | SLC34A1 3965/4885KDM4E 507/4885CYP2C19 3/4885 |
| US-20170362192-A1 | PROCESS FOR PREPARING ATALUREN AND ITS INTERMEDIATES | AGT, AGTR1, GRHPR | SLC34A1 2440/4885KDM4E 1858/4885CYP2C19 143/4885 |
| US-10138215-B2 | Process for preparing ataluren and its intermediates | AGT, AGTR1, GRHPR | SLC34A1 2440/4885KDM4E 1858/4885CYP2C19 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.